This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.

Inclusion Criteria:

• Adults aged ≥ 20 years
• Patients who have understood and signed the informed consent.
• Subjects who have been confirmed histologically and radiologically for non small cell lung cancer and are scheduled to receive treatment with immune checkpoint inhibitors
• Subjects whose urine HCG are negative and who have agreed with the appropriate method of contraception in case of women of childbearing potential
• Subjects who can fully communicate with their medical doctor about their symptoms or quality of life and who can fill out questionnaires
• Subjects who can follow up during the clinical trial
• Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
• Hemoglobin ≥ 9g/dL

Exclusion Criteria:

• Subjects who are pregnant, breastfeeding, planning to become pregnant or women of childbearing potential who do not agree with the appropriate method of contraception
• Subjects who have symptomatic and uncontrolled brain or central nervous system metastasis
• Subjects who complain of uncontrolled pain despite using analgesics
• Diastolic Blood Pressure>100mmHg or Systolic Blood Pressure>160mmHg
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels higher than 2.5 times the upper limit for normal
• Creatinine level higher than 1.5 times the upper limit for normal
• Subjects who have participated in other clinical trials within 1 months
• Subjects with a history of serious drug allergies or who have hypersensitivity to the Investigational Product (the main ingredient and its components)
• Subjects with autoimmune diseases
• Subjects who have alcoholism or drug dependence
• Subjects who have cognitive impairment or psychiatric problems
• Subjects who have undergone surgery within 2 weeks
• Subjects who took other herbal medicine or other medicines within 4 weeks
• Subjects who have a medical condition that is likely to affect results or who are determined to be inappropriate to participate in this clinical trial at the investigator